iRGD‐modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation

Dan Lin,Haiyang Zhang,Rui Liu,Ting Deng,Tao Ning,Ming Bai,Yuchong Yang,Kegan Zhu,Junyi Wang,Jingjing Duan,Shaohua Ge,Bei Sun,Guoguang Ying,Yi Ba
DOI: https://doi.org/10.1002/1878-0261.13052
2021-07-22
Molecular Oncology
Abstract:<p>Fatty acid oxidation (FAO) plays a vital role in drug resistance in cancer cells. Carnitine palmitoyltransferase 1A (<i>CPT1A</i>), a key enzyme of FAO, is widely recognized as an emerging therapeutic target. Here, we confirmed that <i>CPT1A</i> was heterogeneously expressed in colon cancer cells, with a high expression in oxaliplatin-resistant cells but low expression in oxaliplatin-sensitive cells, and expression could be increased by oxaliplatin stimulation. In addition, we verified that <i>CPT1A</i> was more highly expressed in colon cancer tissues than in noncancerous tissues. Silencing <i>CPT1A</i> by siRNA or etomoxir, a specific small-molecule inhibitor of <i>CPT1A</i>, could reverse the sensitivity of drug-resistant colon cancer cells to oxaliplatin. Subsequently, the combination of oxaliplatin with <i>CPT1A</i> inhibition promoted apoptosis and inhibited proliferation. In addition, exosomes were generated with the iRGD peptide on the surface, which showed highly efficient targeting compared to control exosomes <i>in vivo</i>. Furthermore, we loaded and therapeutically applied iRGD-modified exosomes with si<i>CPT1A</i> to specifically deliver si<i>CPT1A</i> into tumours to suppress FAO. As a consequence, iRGD-modified exosomes showed the significant inhibition of <i>CPT1A</i> in tumour tissues, and exhibited the ability to reverse oxaliplatin resistance and inhibit tumour growth by inhibiting FAO with high safety <i>in vivo</i>.</p>
oncology
What problem does this paper attempt to address?